PPARG and metabolic dysfunction-associated steatotic liver disease: A significant (≥1.5‐fold) increase in plasma ADPN requires a much larger weight loss, as observed after bariatric surgery,52 but still the change is less than that observed with PPAR‐γ agonists in patients with NAFLD.22, 31, 49, 50